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Dosing, durability of haemoglobin response and safety of iron isomaltoside in outpatients 
with gastrointestinal diseases 
Introduction 
 Iron deficiency anaemia (IDA) 
commonly complicates gastrointestinal 
disease and impairs quality of life (QoL).  
 Intravenous iron therapy is widely used 
in IDA when oral iron is poorly tolerated 
or ineffective 
 Normalisation of haemoglobin improves 
QoL scores.  
 We sought to define the dosing 
regimens of, durability of haemoglobin 
responses and the prevalence of 
adverse events to intravenous iron (III) 
isomaltoside (Monofer) 
Methods 
 Service evaluation of intravenous iron use 
in 505 outpatients (40% male) with 
gastrointestinal disease treated with 645 
Monofer infusions between 2014 and 
2017.  
 Demographic, diagnosis, and treatment 
factors including dose of Monofer used 
and the number of patients treated with 
repeat infusions, recorded from the 
medical record.  
 Anaemia was defined by WHO criteria 
(haemoglobin <130 g/L in men, 120 g/L in 
women).  
 Iron deficiency was defined as transferrin 
saturation <18% and/or ferritin <30 µg/L 
(ferritin <100 µg/L if CRP >5 mg/L).  
 We extracted laboratory results from the 
electronic record for baseline, 12 weeks 
and 52 weeks.  
 We sought factors associated with 
treatment failure, defined as ongoing 
anaemia at 12 weeks, using logistic 
regression. 
Results 
 Overall, 93% (568/613) were anaemic at baseline with 
median (IQR) haemoglobin of 100 g/L (IQR 88-112). 
 73% (473/645) had recent haematinics tested and 90% of 
those (423/473) had proven IDA. 
 Inflammatory bowel disease was the most common 
indication, 30% (193/645) of infusions. (Figure 1) 
 A variety of dosing regimens were used: 26% (165/645) 
received fixed dosing of 1 g, 25% (163/645) were dosed 
according to the Ganzoni formula, 14% (91/648) had the 
dose calculated by the Ganzoni formula but limited to a 
single 20 mg/kg infusion, 8% (54/645) were dosed by the 
simplified dosing table and 27% (172/648) other dosing 
strategies. 74% (476/645) infusions had follow-up 
haemoglobin measured 6 to 18 weeks post-infusion.  
 The median change in haemoglobin between baseline and 
6-18 weeks was 18 g/L (IQR 8-29). 42% (185/438) of 
previously anaemic patients had normalised their 
haemoglobin by this time.  
 Factors associated with failure to normalise haemoglobin 
on multivariable analysis were male sex (odds ratio (OR) 2.7 
[95%CI 1.7-4.3]), higher comorbidity (Charlson score ≥ 4) 
(OR 1.9 [95%CI 2.6-5.5]) and under-dosing versus Ganzoni-
calculated dose (OR 2.3 per gram underdosed [95%CI 1.0-
5.2]). Only, 31% (44/143) patients whose haemoglobin 
normalised at week 12 had recurrent anaemia at 1 year.  
 Haemoglobins over time with an indication of over-and 
under-dosing are displayed in figure 2. 
 Adverse events were rare: only two patients had a probable 
complement activation-related pseudo allergy that was 
mitigated by slowing infusions, and one an anaphylactic 
reaction. 
A wide-variety of dosing strategies are used in our trust.  
Treatment failure was associated with under-dosing , sex and comorbidity.  
Adverse events were rare. 
Conclusions 
Figure 1: Indication for iron infusions 
Figure 2: Haemoglobin change post iron infusion; boxes indicate medians/interquartile ranges 
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